COPDGene 研究中疑似间质性肺病的发生、进展与死亡率
在 COPDGene 队列中,基于间质性肺异常(ILA)和纤维化或 FVC<80% 定义疑似 ILD。入选时 268/9588 例(2.8%)存在疑似 ILD,中位 10.6 年死亡率 51%,高于单纯 ILA 的 33%(HR 2.0,P<0.001)。5 年随访中仅 CT 进展者死亡率亦高于 ILA(HR 2.6,P=0.005)。
要点
- 疑似 ILD 死亡率高于单纯 ILA(51% vs 33%,HR 2.0)
- 仅满足纤维化标准者死亡率更高(58%,HR 2.2)
- 仅 CT 进展者死亡率高于 ILA(HR 2.6)
核心结论
- 疑似 ILD 患者死亡率和进展率均较高。
- 纤维化和影像学进展是死亡的重要预测因素。
研究设计与样本
- COPDGene 队列研究,纳入有 ILA 特征且入组及 5 年随访时有 FVC 的参与者。
- 入组时 9588 例,其中 268 例(2.8%)存在疑似 ILD。
- 疑似 ILD 定义为 ILA 且伴纤维化和/或 FVC<80% 预计值。
主要发现
- 疑似 ILD 中位 10.6 年死亡率 51%,高于单纯 ILA 的 33%(HR 2.0,P<0.001)。
- 仅纤维化标准(FVC≥80%)亚组死亡率 58%,高于 ILA(HR 2.2,P<0.001)。
- 98 例疑似 ILD 完成 5 年随访:33% 稳定,6% 仅 FVC 下降≥10%,39% 仅 CT 进展,22% CT 进展且 FVC 下降≥10%。
- 上述四组死亡率分别为 31%、50%、45%、45%;仅 CT 进展者死亡率高于 ILA(HR 2.6,P=0.005)。
- 5 年随访时,无疑似 ILD 者中新发 ILD 148/4842 例(5.5/1000 人年),死亡率高于 ILA(HR 2.4,P<0.001)。
关键数值与推荐
- 疑似 ILD 定义:ILA 且纤维化和/或 FVC<80% 预计值。
- CT 进展采用视觉评估,FVC 进展采用相对变化。
临床怎么用
- 对 COPD 患者应关注 ILA 及纤维化、FVC 下降和 CT 进展,以识别高死亡风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Some with interstitial lung abnormalities (ILA) are suspected to have interstitial lung disease (ILD), a subgroup with adverse outcomes. Rates of development and progression of suspected ILD and their effect on mortality are unknown. Objectives: To determine rates of development, progression, and mortality in those with suspected ILD and assess effects of individual ILD and progression criteria. Methods: Participants from COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) with ILA characterization and FVC at enrollment and 5-year follow-up were included. ILD was defined as ILA and fibrosis and/or FVC < 80% predicted. Prevalent ILD was assessed at enrollment and incident ILD and progression were assessed at 5-year follow-up. Computed tomography (CT) progression was assessed visually and FVC decline as relative change. Multivariable Cox regression tested associations between mortality and prevalent ILD, incident ILD, and progression groups. Measurements and Main Results: Of 9,588 participants at enrollment, 268 (2.8%; 51% of ILA) had prevalent ILD. Those with prevalent ILD had 51% mortality after median 10.6 years, which was higher than those with ILA without prevalent ILD (henceforth ILA) (33%; hazard ratio [HR], 2.0; P < 0.001). The subgroup of prevalent ILD with only fibrosis criteria (FVC ≥ 80%) had worse mortality (58%) than ILA (HR, 2.2; P < 0.001). A total of 98 participants with prevalent ILD completed 5-year follow-up: 33% had stable CT and relative FVC decline <10%, 6% had FVC decline ≥10% only, 39% had CT progression only, and 22% had both CT progression and FVC decline ≥10%. Mortality rates were 31%, 50%, 45%, and 45%, respectively; those with only CT progression had worse mortality than those with ILA (HR, 2.6; P = 0.005). At 5-year follow-up, incident ILD occurred in 148/4,842 participants without prevalent ILD (5.5/1,000 person-years) and had worse mortality than ILA (HR, 2.4; P < 0.001). Conclusion: Rates of mortality and progression are high among those with suspected ILD in COPDGene; fibrosis and radiologic progression are important predictors of mortality.
引用
- Rose JA, Tukpah AC, Cutting C, et al. Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene. Am J Respir Crit Care Med. 2024. PMID: 39133466. doi:10.1164/rccm.202402-0313OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。